The effect of bucolome and amiodarone, inhibitors of CYP2C9, on the pharmacokinetics of losartan

被引：0
|
作者：
Takagi, Miho [1 ]
Kobayashi, Mariko [1 ]
Fukumoto, Kyoko [1 ]
Ueno, Kazuyuki [1 ]
机构：
[1] Niigata Univ, Dept Pharmaceut Sci, Niigata, Japan
来源：
THERAPEUTIC DRUG MONITORING | 2007年 / 29卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
240
引用
收藏
页码：534 / 535
页数：2
相关论文
共 50 条
  • [1] The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan
    Kobayashi, Mariko
    Takagi, Miho
    Fukumoto, Kyoko
    Kato, Ryuji
    Tanaka, Kazuhiko
    Ueno, Kazuyuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) : 115 - 119
  • [2] Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects
    Huang, Hang-Xing
    Wu, He
    Zhao, Yingying
    Zhou, Tao
    Ai, Xin
    Dong, Yu
    Zhang, Yan
    Lai, Yong
    XENOBIOTICA, 2021, 51 (05) : 616 - 623
  • [3] Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
    Bae, Jung-woo
    Choi, Chang-ik
    Kim, Mi-jeong
    Oh, Da-hee
    Keum, Seul-ki
    Park, Jung-in
    Kim, Bo-hye
    Bang, Hye-kyoung
    Oh, Sung-gon
    Kang, Byung-sung
    Lee, Hye-in
    Lee, Yun-jeong
    Park, Hyun-joo
    Kim, Hae-deun
    Ha, Ji-hey
    Shin, Hee-jung
    Kim, Young-hoon
    Na, Han-sung
    Chung, Myeon-woo
    Han, Soon-young
    Kim, Seung-hee
    Jang, Choon-gon
    Lee, Seok-yong
    ACTA PHARMACOLOGICA SINICA, 2011, 32 (10) : 1303 - 1308
  • [4] The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics.
    Meadowcroft, AM
    Williamson, KM
    Patterson, JH
    Hinderliter, AL
    Pieper, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 213 - 213
  • [5] Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
    Jung-woo Bae
    Chang-ik Choi
    Mi-jeong Kim
    Da-hee Oh
    Seul-ki Keum
    Jung-in Park
    Bo-hye Kim
    Hye-kyoung Bang
    Sung-gon Oh
    Byung-sung Kang
    Hyun-joo Park
    Hae-deun Kim
    Ji-hey Ha
    Hee-jung Shin
    Young-hoon Kim
    Han-sung Na
    Myeon-woo Chung
    Choon-gon Jang
    Seok-yong Lee
    Acta Pharmacologica Sinica, 2011, 32 : 1303 - 1308
  • [6] Effect of CYP2C9 genotype on losartan disposition.
    Pieper, JA
    Lee, CR
    Hinderliter, AL
    Clarke, MJ
    Blaisdell, JA
    Goldstein, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P68 - P68
  • [7] Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of losartan
    Bae, Jung-Woo
    Han, Ho-Kyun
    Lee, Hwan-Joo
    Jung, Dong -Won
    Kim, Nam-Tae
    Lee, Jin-Hee
    Jang, Choon-Gon
    Choi, Sun-Ok
    Kim, Ok-Hee
    Lee, Seok-Yong
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 230 - 231
  • [8] The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
    Meadowcroft, AM
    Williamson, KM
    Patterson, JH
    Hinderliter, AL
    Pieper, JA
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (04): : 418 - 424
  • [9] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
    Sekino, K
    Kubota, T
    Okada, Y
    Yamada, Y
    Yamamoto, K
    Horiuchi, R
    Kimura, K
    Iga, T
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 589 - 592
  • [10] Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects
    Kazuishi Sekino
    Takahiro Kubota
    Yuko Okada
    Yasuhiko Yamada
    Koujirou Yamamoto
    Ryuya Horiuchi
    Kenjirou Kimura
    Tatsuji Iga
    European Journal of Clinical Pharmacology, 2003, 59 : 589 - 592
12345